Results 71 to 80 of about 13,550 (188)

Association of bla_VIM-2, bla_PDC-35, bla_OXA-10, bla_OXA-488 and bla_VEB-9 β-Lactamase Genes with Resistance to Ceftazidime–Avibactam and Ceftolozane–Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa

Antibiotics, 2022
Ceftazidime–avibactam and ceftolozane–tazobactam are approved for the treatment of complicated Gram-negative bacterial infections including multidrug-resistant (MDR) Pseudomonas aeruginosa.
Mazen A. Sid Ahmed, Faisal Ahmad Khan, Hamad Abdel Hadi, Sini Skariah, Ali A. Sultan, Abdul Salam, Abdul Latif Al Khal, Bo Söderquist, Emad Bashir Ibrahim, Ali S. Omrani, Jana Jass   +10 more
doaj   +1 more source

Activity of ceftazidime•avibactam against multidrug-resistance Enterobacteriaceae expressing combined mechanisms of resistance

Enfermedades infecciosas y microbiologia clinica (English ed.), 2017
Antimicrobial resistance in Enterobacteriaceae is increasing worldwide and is making treating infections caused by multidrug-resistant Enterobacteriaceae a challenge. The use of β-lactam agents is compromised by microorganisms harboring extended-spectrum β-lactamases (ESBLs) and other mechanisms of resistance.
López-Hernández, Inmaculada, Alonso, Noemí, Fernández-Martínez, Marta, Zamorano, Laura, Rivera, Alba, Oliver, Antonio, Conejo, M. Carmen, Martínez-Martínez, Luis, Navarro, Ferrán, Pascual, Alvaro   +9 more
openaire   +4 more sources

EMERGENCE OF CEFTAZIDIME-AVIBACTAM RESISTANCE IN ENTERO-BACTERALES AND PSEUDOMONAS AERUGINOSA

Pakistan Journal of Pathology, 2023
Objective: The objective of this study is to determine the emergence of resistance to Ceftazidime-Avibactam (CAZ-AVI) by Enterobacterales and Pseudomonas aeruginosa in clinical isolates. Material and Methods: In this cross-sectional study (6-months) March-August 2022 Carbapenem resistant Enterobacterales were tested for Ceftazidime-Avibactam (30/20 µg,
Alina Mehwish, Irim Iftikhar
openaire   +1 more source

Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent Klebsiella pneumoniae

Virulence
Objectives This study aimed at revealing the underlying mechanisms of the loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing hypervirulent Klebsiella pneumoniae (hvKp).Methods Here we longitudinally recovered 3 non ...
Jiankang Zhao, Danni Pu, Ziyao Li, Yulin Zhang, Xinmeng Liu, Xianxia Zhuo, Binghuai Lu, Bin Cao   +7 more
doaj   +1 more source

Risk factors for mortality in patients treated with ceftazidime-avibactam for ceftazidime-avibactam susceptible carbapenem-resistant Klebsiella pneumoniae bacteremia

Journal of Infection and Public Health
Ceftazidime-avibactam (CZA) is the preferred treatment for infections caused by carbapenem-resistant Klebsiella pneumoniae (CRKP). This study aimed to investigate the prognostic factors of 28-day mortality and 14-day clinical failure in patients treated with CZA for CZA-susceptible CRKP bacteremia.Patients with CZA-susceptible CRKP bacteremia who ...
Yi-Tsung Lin, Shih-Neng Lin, Chien Chuang, Szu-Yu Liu, Yu-Chien Ho, Chih-Han Juan, Hsiang-Ling Ho, Sheng-Hua Chou   +7 more
openaire   +3 more sources

Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.

Journal of global antimicrobial resistance, 2021
Clinical experience with ceftazidime-avibactam (CAZ-AVI) for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections is not well evaluated. The aim of this study was to assess its efficacy in a single-centre cohort of patients infected with CR-KP.We conducted a retrospective observational study of consecutive patients treated for
Jie, Gu, Jie, Xu, Ting-Ting, Zuo, Yan-Bin, Chen   +3 more
openaire   +1 more source

Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination

, 2013
Avibactam (formerly NXL104, AVE1330A) is a synthetic non-β-lactam, β-lactamase inhibitor that inhibits the activities of Ambler class A and C β-lactamases and some Ambler class D enzymes. This review summarizes the existing data published for ceftazidime-
Hoban, Daryl J., Zhanel, George G., Karlowsky, James A., Adam, Heather, Lawson, Christopher D., Schweizer, Frank, Gin, Alfred S., Lynch, Joseph P., Zelenitsky, Sheryl, Denisuik, Andrew, Rubinstein, Ethan, Lagacé-Wiens, Philippe R. S.   +11 more
core   +1 more source

The importance of monitoring a new antibiotic: ceftazidime/avibactam usage and resistance experience from England, 2016 to 2020

Eurosurveillance
Background Ceftazidime/avibactam, launched in the United Kingdom (UK) in March 2017, is an antibiotic against multidrug-resistant Gram-negative pathogens.
Berit Muller-Pebody
doaj   +1 more source

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection

Microbiology Spectrum
KPC-producing Klebsiella pneumoniae infections are a rising global health threat. The factors driving blaKPC mutations during treatment and their contribution to infection persistence remain unclear.
Feng Yang, Weiwei Yang, Jinghao Zhang, Chengkang Tang, Li Ding, Siquan Shen, Yanhao Zhou, Hongyu Zhao, Jiaojiao Zhou, Fupin Hu   +9 more
doaj   +1 more source

ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa [PDF]

, 2019
To evaluate the efficacy of the recently launched β-lactam/β-lactamase inhibitor combinations ceftazidime/avibactam and ceftolozane/tazobactam against ESBL- producing Escherichia coli and Pseudomonas aeruginosa strains.Methods: A series of ESBL ...
Ortiz de la Rosa, José-Manuel, Nordmann, Patrice, Poirel, Laurent   +2 more
core